{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Niu Y"],"pubmed_abstract":["<h4>Objectives</h4><i>Trigonella foenum-graecum</i> L. (HLB) exhibits promising pharmacological properties for the treatment of type 2 diabetic nephropathy (DN). This study aims to enhance the understanding of HLB's pharmacodynamic effects and elucidate the mechanisms underlying its therapeutic potential in DN.<h4>Methods</h4>The pharmacodynamic effects of HLB were initially evaluated in a murine DN model through the oral administration of an aqueous extract of HLB. The primary bioactive constituents were subsequently identified using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS). Network pharmacology analysis was integrated with these data to uncover potential molecular targets of HLB in DN. Key renal metabolites were profiled usi"],"journal":["Frontiers in pharmacology"],"pagination":["1566723"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11959092"],"repository":["biostudies-literature"],"pubmed_title":["&lt;i&gt;Trigonella foenum-graecum&lt;/i&gt; L. protects against renal function decline in a mouse model of type 2 diabetic nephropathy by modulating the PI3K-Akt-ERK signaling pathway."],"pmcid":["PMC11959092"],"pubmed_authors":["Chi L","He X","Li P","Pang Z","Du J","Wang X","Niu H","Niu Y","Lu B"],"additional_accession":[]},"is_claimable":false,"name":"&lt;i&gt;Trigonella foenum-graecum&lt;/i&gt; L. protects against renal function decline in a mouse model of type 2 diabetic nephropathy by modulating the PI3K-Akt-ERK signaling pathway.","description":"<h4>Objectives</h4><i>Trigonella foenum-graecum</i> L. (HLB) exhibits promising pharmacological properties for the treatment of type 2 diabetic nephropathy (DN). This study aims to enhance the understanding of HLB's pharmacodynamic effects and elucidate the mechanisms underlying its therapeutic potential in DN.<h4>Methods</h4>The pharmacodynamic effects of HLB were initially evaluated in a murine DN model through the oral administration of an aqueous extract of HLB. The primary bioactive constituents were subsequently identified using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS). Network pharmacology analysis was integrated with these data to uncover potential molecular targets of HLB in DN. Key renal metabolites were profiled usi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-07-11T03:04:03.998Z","creation":"2025-07-11T03:04:03.998Z"},"accession":"S-EPMC11959092","cross_references":{"pubmed":["40170727"],"doi":["10.3389/fphar.2025.1566723"]}}